AdBio partners | LinkedIn (original) (raw)
``
Directeurs du capital-risque et du capital-investissement
Paris, IDF 3 649 abonnés
AdBio is a VC firm with an entrepreneurial spirit, dedicated to life sciences & focusing on early-stage investments
À propos
AdBio partners focuses on ground-breaking innovations in Life Sciences to address unmet medical and clinical needs, building the next generation of pioneering healthcare companies. Keeping in mind patients’ well-being, we believe in improving medical care and taking medical innovations further ahead. We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success. We embrace French Life Sciences’ dynamic of innovation. France harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. Adbio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring France’s biotechnology ecosystem. Adbio partners was founded in 2015 and is AMF regulated since 2016.
Secteur
Directeurs du capital-risque et du capital-investissement
Taille de l’entreprise
2-10 employés
Siège social
Paris, IDF
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2016
Lieux
Employés chez AdBio partners
Nouvelles
- [Portfolio news] We are thrilled to share that Colin Bond has joined Agomab an Independent Director and Chairman of the Audit Committee. Colin’s extensive financial leadership, with over 30 years of expertise, including his tenure as CFO at Sandoz, positions him perfectly to support Agomab 's continued growth. Colin’s experience spans strategic roles at global pharmaceutical leaders, and his track record in guiding companies through pivotal growth stages will be invaluable as Agomab advances its portfolio targeting fibrotic diseases. At AdBio partners, we take immense pride in seeing our portfolio companies attract top-tier talent to fuel their ambitions. Congratulations to Colin Bond – we’re excited to see what’s next
David Epstein Alain Huriez #Leadership #AgomabTherapeutics #Biotech #LifeSciences #VentureCapital
We are excited to welcome Colin Bond, who joins our Board of Directors as an Independent Director and Chairman of the Audit Committee. Colin brings three decades of finance experience to Agomab, including fifteen years as a CFO for biopharmaceutical companies in the EU and US; most recently he served as CFO at Sandoz. We look forward to leveraging Colin’s deep knowledge in the financial, pharmaceutical and public markets as we progress towards the next growth stage for Agomab. Find the full announcement here: https://bit.ly/4eAoHMR #Leadership #Agomab #AgomabTherapeutics #BoardAnnouncement -
3 649 abonnés
2 sem. Modifié
[Portfolio news] At AdBio partners, we are deeply committed to creating and shaping innovative companies from their earliest stages, transforming scientific breakthroughs into impactful therapies. We’re proud to announce today the launch of AndzonBio1 with a first €3M financing with Inserm Transfert. As the first in a series of thematic studios within AndzonBio, AndzonBio1 will focus on Cardiovascular, Renal, and Metabolic (CVRM) diseases—a field with important unmet medical needs. Through AndzonBio, we are pursing our #HandsOn mission, accelerating science, guiding promising ideas from the lab towards the patients. Stay tuned for updates here : https://andzonbio1.com/ Karine Charton Vincent Bischoff Loïc Lhuillier Alain Huriez
85 abonnés
2 sem. Modifié
🚀 Great News 🚀 We are excited to unveil AndzonBio1, the first start-up studio to emerge from the AndzonBio® Model launched by Inserm Transfert and AdBio partners, with €3m of seed funding! 💶 At AndzonBio1, we’re committed to developing breakthrough therapeutic innovations for the treatment of Cardiovascular, Renal and Metabolic diseases ! 💡 Check out our new website: https://andzonbio1.com/ to learn more about our team and approach. And stay tuned, we have some exciting projects to come soon! 📢 #biotech #academicscience #innovation #startups #AndzonBio #lifesciences #venturecapital #cardiovascular #renal #metabolism AdBio partners Inserm Transfert Karine Charton Vincent Bischoff Loïc Lhuillier Armelle Sérose, Ph.D. - [Portfolio news] We are excited to announce a $89 million Series D financing round for our portfolio company Agomab, lead by new investors Sanofi and The Invus Group. Agomab is developping a pipeline of therapies for Fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. These innovations aim to tackle the significant challenges patients face everyday, including pain and the need for surgery. At AdBio partners, we remain committed to supporting solutions that have a meaningful impact on patients' lives. Congratulations to the team on this important milestone
#UnmetNeeds #PatientImpact #Innovation Tim Knotnerus Alain Huriez
- [Portfolio news] We’re proud to share that ARTHEx Biotech, a company we have supported since 2020, has dosed its first patient in the Phase I-IIa ArthemiR™ trial for Myotonic Dystrophy Type 1 (DM1)! This is a great success for ARTHEx Biotech, and a powerful validation of our model at AdBio partners — shaping early-stage, high-potential innovations and guiding them all the way to the clinic. 💡 From the first check to the first patient, we’ve believed in the potential of the project, the industry’s first anti-microRNA therapeutic for DM1. It’s moments like these — bringing transformative therapies to patients — that fuel our vision and drive us every day. This is why we do what we do. Huge congratulations to the entire Arthex team! Frederic LEGROS Judith Walker beatriz llamusi Alain Huriez Adrien C.
6 913 abonnés
1 mois Modifié
#BREAKING: Today, we are thrilled to announce the first participant has been dosed in the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1), the industry’s first anti-microRNA therapeutic to be investigated in persons living with DM1. ATX-01 is an antimiR oligonucleotide designed to target microRNA 23b (miR-23b), which is involved in the pathogenesis of DM1. It has been demonstrated, in human DM1 primary myoblasts and in two murine models, that ATX-01 has a dual mechanism of action which reduces toxic DMPK mRNA and increases MBNL protein production. Click here to learn more: https://lnkd.in/gg2JWx3MVisit our #Patients page on our website too: https://lnkd.in/gVNxdQVHLearn more about the dual mechanism of our AntimiR™ technology here: https://lnkd.in/gnmFvjHv #RNAInnovation #MicroRNA #Biotech #MyotonicDystrophy #DM1 #FirstPatientDosed -
3 649 abonnés
1 mois Modifié
[Job offer] AdBio partners is strengthening its team in Spain and #hiring an Analyst based in the Barcelona Office. Join a dynamic team dedicated to transform academic research into therapies for patients ! Check out the offer below 👇 Please submit your resume and cover letter to contact@adbio.partners - |Portfolio news] We are proud to welcome David Epstein as Chairman of the Board of Agomab ! David is renowned for his transformative leadership in the biopharmaceutical field, having been recognized as one of the top 25 most influential figures in biopharma. David was CEO of Novartis Pharmaceuticals and of Seagen until its acquisition by Pfizer in a $43 billion deal last december. With a track record of over 30 new molecular entities to his name, David's expertise is set to propel Agomab 's mission to develop innovative treatments for fibrotic diseases. This appointment underscores our commitment at AdBio partners to attract international talents to our companies. We believe David’s extensive experience and leadership will be instrumental in helping Agomab 's treatments reach patients. Welcome on board, David! Tim Knotnerus Alain Huriez
7 398 abonnés
4 mois Modifié
We are very pleased to welcome David Epstein as our new Chairman of the Board of Directors at Agomab. David is a distinguished leader in the biopharmaceutical industry, who served most recently as Seagen’s Chief Executive Officer until the company was acquired for more than $43 billion by Pfizer. Prior to Seagen, David served as Novartis Pharmaceuticals’ Chief Executive Officer. We look forward to working closely with him and leveraging his experience to advance our mission of developing innovative treatments for fibrotic diseases. We also want to deeply thank our previous Chair, John Haurum, who was an instrumental guide during a transformational period for the company and accompanied us through major milestones. Read the full announcement here https://lnkd.in/ehatPxHf #Leadership #AgomabTherapeutics #BoardAnnouncement -
3 649 abonnés
4 mois Modifié
[Portfolio news] We’re proud to announce that Augustine Therapeutics has raised a €17 million ($18.5 million) #SeriesA to develop its pipeline for neurodegenerative and cardiometabolic diseases. Warm welcome to our new partners, Asabys Partners, Eli Lilly and Company, and CMT Research Foundation & to Gerhard Koenig, Chairman of the board.Alain Huriez Adrien C. Sylvain Celanire
NEWS ALERT! 📢 We are excited to announce the completion of a €17 million ($18.5 million) Series A first close to advance our differentiated HDAC6 inhibitor pipeline to the clinic and support expansion of our R&D and management team. This funding round is led by Asabys Partners, with the participation of Eli Lilly and Company and the US CMT Research Foundation, alongside continued support from our historical investors PMV, AdBio partners, V-Bio Ventures, VIB and GEMMA FRISIUS - FONDS K.U.LEUVEN. As part of this milestone, we welcome Clara Campàs Moya, Managing Partner and co-founder of Asabys Partners, to the Augustine Board of Director, and announce the appointment of Gerhard Koenig as executive Chairman. Stay tuned 🔊 for further updates as we prepare to transition into the clinic with our lead program! To learn more, read the full press release here: https://lnkd.in/eVtvQUdv #AugustineTx #SeriesA #CMT